JP2006519807A - 癌およびmapキナーゼ関連疾患の処置のためのイソキノリン誘導体の使用 - Google Patents

癌およびmapキナーゼ関連疾患の処置のためのイソキノリン誘導体の使用 Download PDF

Info

Publication number
JP2006519807A
JP2006519807A JP2006504625A JP2006504625A JP2006519807A JP 2006519807 A JP2006519807 A JP 2006519807A JP 2006504625 A JP2006504625 A JP 2006504625A JP 2006504625 A JP2006504625 A JP 2006504625A JP 2006519807 A JP2006519807 A JP 2006519807A
Authority
JP
Japan
Prior art keywords
substituted
phenyl
lower alkyl
unsubstituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006504625A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006519807A5 (https=
Inventor
デイビッド・ブライアント・バット
グイド・ボルト
スンキュ・キム
ティモシー・マイケル・ラムジー
マイケル・ロイド・サビオ
Original Assignee
ノバルティス アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アクチエンゲゼルシャフト filed Critical ノバルティス アクチエンゲゼルシャフト
Publication of JP2006519807A publication Critical patent/JP2006519807A/ja
Publication of JP2006519807A5 publication Critical patent/JP2006519807A5/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2006504625A 2003-03-11 2004-03-10 癌およびmapキナーゼ関連疾患の処置のためのイソキノリン誘導体の使用 Pending JP2006519807A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45362403P 2003-03-11 2003-03-11
PCT/EP2004/002460 WO2004080464A1 (en) 2003-03-11 2004-03-10 Use of isoquinoline derivatives for treating cancer and map kinase related diseases

Publications (2)

Publication Number Publication Date
JP2006519807A true JP2006519807A (ja) 2006-08-31
JP2006519807A5 JP2006519807A5 (https=) 2007-04-26

Family

ID=32990797

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006504625A Pending JP2006519807A (ja) 2003-03-11 2004-03-10 癌およびmapキナーゼ関連疾患の処置のためのイソキノリン誘導体の使用

Country Status (22)

Country Link
EP (1) EP1603566B1 (https=)
JP (1) JP2006519807A (https=)
KR (1) KR20050108383A (https=)
CN (1) CN1758910A (https=)
AT (1) ATE421324T1 (https=)
AU (1) AU2004218914A1 (https=)
BR (1) BRPI0408257A (https=)
CA (1) CA2518530A1 (https=)
DE (1) DE602004019193D1 (https=)
ES (1) ES2318276T3 (https=)
HR (1) HRP20050788A2 (https=)
IS (1) IS8064A (https=)
MA (1) MA27724A1 (https=)
MX (1) MXPA05009687A (https=)
NO (1) NO20054647L (https=)
PL (1) PL1603566T3 (https=)
PT (1) PT1603566E (https=)
RU (1) RU2325159C2 (https=)
TN (1) TNSN05223A1 (https=)
TW (1) TW200501955A (https=)
WO (1) WO2004080464A1 (https=)
ZA (1) ZA200506571B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009077712A (ja) * 2007-09-11 2009-04-16 F Hoffmann La Roche Ag B−Rafキナーゼ阻害剤に対する感受性についての診断試験
JP2014500864A (ja) * 2010-10-28 2014-01-16 ヴィアメット ファーマスーティカルズ,インコーポレイテッド 金属酵素阻害化合物

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05012377A (es) 2003-05-15 2006-05-25 Arqule Inc Derivados de imidazotiazoles e imidazoxazol como inhibidores de p38.
AR045944A1 (es) * 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
WO2006010082A1 (en) 2004-07-08 2006-01-26 Arqule, Inc. 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase
JP2008517064A (ja) 2004-10-19 2008-05-22 アークル インコーポレイテッド P38mapキナーゼのイミダゾオキサゾールおよびイミダゾチアゾール阻害剤の合成
CN101160131A (zh) * 2005-02-25 2008-04-09 诺瓦提斯公司 Bcr-abl和raf抑制剂的药物组合产品
JP5049970B2 (ja) * 2005-07-26 2012-10-17 サノフイ Rho−キナーゼ阻害剤としてのシクロヘキシルアミンイソキノロン誘導体
US8318941B2 (en) 2006-07-06 2012-11-27 Bristol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
EP3284494A1 (en) 2009-07-30 2018-02-21 Tandem Diabetes Care, Inc. Portable infusion pump system
CN103038364A (zh) 2010-03-09 2013-04-10 达纳-法伯癌症研究所公司 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法
CN103435430B (zh) * 2013-08-08 2015-02-18 四川大学 一种还原酰胺类化合物的方法
KR102119943B1 (ko) 2018-05-23 2020-06-05 주식회사 포스코 시편배치유닛 및 이를 포함하는 도장밀착성 실험장치
US20210275516A1 (en) * 2018-07-02 2021-09-09 Ecole Polytechnique Federale De Lausanne (Epfl) Lactate enhancing compounds and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009495A1 (en) * 1998-08-11 2000-02-24 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
WO2001023375A2 (en) * 1999-09-28 2001-04-05 Bayer Corporation Substituted pyridines and pyridazines with angiogenesis inhibiting activity
WO2001058899A1 (en) * 2000-02-09 2001-08-16 Novartis Ag Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
JP2006503796A (ja) * 2001-12-21 2006-02-02 バイエル・フアーマシユーチカルズ・コーポレーシヨン ピリダジンまたはピリジン誘導体を含んでなる抗−脈管形成組み合わせ療法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
US20030078271A1 (en) * 2001-01-31 2003-04-24 Blackburn Thomas P. Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
DE60239097D1 (de) * 2001-03-02 2011-03-17 Gpc Biotech Ag Drei-hybrid-assaysystem
US7220775B2 (en) * 2002-08-07 2007-05-22 H. Lundbeck A/S Compound useful for the treatment of neuropathic pain

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009495A1 (en) * 1998-08-11 2000-02-24 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
WO2001023375A2 (en) * 1999-09-28 2001-04-05 Bayer Corporation Substituted pyridines and pyridazines with angiogenesis inhibiting activity
WO2001058899A1 (en) * 2000-02-09 2001-08-16 Novartis Ag Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
JP2006503796A (ja) * 2001-12-21 2006-02-02 バイエル・フアーマシユーチカルズ・コーポレーシヨン ピリダジンまたはピリジン誘導体を含んでなる抗−脈管形成組み合わせ療法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009077712A (ja) * 2007-09-11 2009-04-16 F Hoffmann La Roche Ag B−Rafキナーゼ阻害剤に対する感受性についての診断試験
JP2014500864A (ja) * 2010-10-28 2014-01-16 ヴィアメット ファーマスーティカルズ,インコーポレイテッド 金属酵素阻害化合物

Also Published As

Publication number Publication date
CN1758910A (zh) 2006-04-12
NO20054647D0 (no) 2005-10-10
MA27724A1 (fr) 2006-01-02
PT1603566E (pt) 2009-04-27
MXPA05009687A (es) 2005-10-20
WO2004080464A1 (en) 2004-09-23
EP1603566B1 (en) 2009-01-21
AU2004218914A1 (en) 2004-09-23
TNSN05223A1 (en) 2007-06-11
DE602004019193D1 (de) 2009-03-12
ATE421324T1 (de) 2009-02-15
HRP20050788A2 (en) 2006-12-31
RU2325159C2 (ru) 2008-05-27
IS8064A (is) 2005-10-10
CA2518530A1 (en) 2004-09-23
PL1603566T3 (pl) 2009-07-31
TW200501955A (en) 2005-01-16
ZA200506571B (en) 2006-07-26
ES2318276T3 (es) 2009-05-01
NO20054647L (no) 2005-12-09
BRPI0408257A (pt) 2006-03-07
RU2005131168A (ru) 2006-05-27
EP1603566A1 (en) 2005-12-14
KR20050108383A (ko) 2005-11-16

Similar Documents

Publication Publication Date Title
US6608071B2 (en) Isoquinoline derivatives with angiogenesis inhibiting activity
JP2007506696A (ja) 増殖性疾患の処置に有用なraf−キナーゼ阻害剤としての1,4−二置換イソキノリン誘導体
EP1165085B1 (en) Phthalazine derivatives for treating inflammatory diseases
EP0970070B1 (en) Phthalazines with angiogenesis inhibiting activity
EP1603566B1 (en) Use of isoquinoline derivatives for treating cancer and map kinase related diseases
JP7055528B1 (ja) プロテアーゼ阻害剤としてのケトアミド誘導体
EP1663234A1 (en) Piperazine derivatives for the treatment of hiv infections
JP2011526295A (ja) 5員および6員複素環化合物
EA023642B1 (ru) Гетеробициклические производные в качестве ингибиторов hcv
US20240174659A1 (en) Compounds and methods for yap/tead modulation and indications therefor
AU2008200070A1 (en) Use of isoquinoline derivatives for treating cancer and MAP kinase related diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070309

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100825

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110114

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110315

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20110415